Latest news

• J&J's Tremfya filed for approval in US for psoriatic arthritis

  The application to the FDA is based on the  top line results from the pivotal phase 3 trials of Tremfya, DISCOVER-1 and DISCOVER-2. ... weeks. These factors could damage Tremfya’s uptake in this indication, if approved, but it’s already established

• Novartis eyes potential new indication for Cosentyx

  This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

• FDA clears Lilly’s Taltz for ankylosing spondylitis

  The drugmaker has also just published data from a trial comparing Taltz to Janssen’s follow-up IL-23 inhibitor Tremfya (ustekinumab) in plaque psoriasis that it thinks could really help ... Tremfya has also been growing quickly since launch, bringing

• NICE’s fast-track catapults Skyrizi into market

  This is even faster than J&J’s rival IL-23 inhibitor Tremfya, which was the first psoriasis treatment to use the fast-track appraisal (FTA) route last year, and which ... of Tremfya – however confidential price agreements for both agents means it

• Leo Pharma to market AstraZeneca’s brodalumab outside Europe

  The psoriasis market is becoming increasingly crowded, with newcomers Taltz from Eli Lilly and Tremfya from Johnson &Johnson demonstrating dramatically improved outcomes in the condition.